This RESCUE and REVERSE Long-Term follow-up (RESTORE) randomized clinical trial investigates the 5-year outcomes of lenadogene nolparvovec gene therapy in patients with Leber hereditary optic neuropathy (LHON) due to the MT-ND4 gene variant.
Visionary News & Insightful Strategy
Footer
A RETINA-SPECIFIC ORGANIZATION
It’s clearly an advantage to work with a consulting group that’s focused on your industry. The team at Retina Consultant has over 50 years of retina-specific experience in healthcare business, practice management, marketing & operations.
We’ve got our eyes on working with the best retina groups and vendors in the industry.
See the best; get in touch.
Recent
- New research links retinal imaging and deep learning to improved schizophrenia detection
- Eyebright Medical receives Class III Certificate from National Medical Products Administration in China for its phakic intraocular lens
- FDA accepts revised supplemental New Drug Application for IZERVAY
- Brimochol PF achieves endpoints in second phase 3 presbyopia trial
- Part B of phase 1/2 X-linked retinoschisis gene therapy trial initiated
Leave a Reply